ASYMCHEM LAB.(TIAN.)H YC1 - Asset Resilience Ratio
ASYMCHEM LAB.(TIAN.)H YC1 (7K90) has an Asset Resilience Ratio of 5.07% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 7K90 net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how ASYMCHEM LAB.(TIAN.)H YC1's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 7K90 asset base.
Liquid Assets Composition Over Time
This chart breaks down ASYMCHEM LAB.(TIAN.)H YC1's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read total liabilities of ASYMCHEM LAB.(TIAN.)H YC1 for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €1.05 Billion | 5.07% |
| Total Liquid Assets | €1.05 Billion | 5.07% |
Asset Resilience Insights
- Limited Liquidity: ASYMCHEM LAB.(TIAN.)H YC1 maintains only 5.07% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
ASYMCHEM LAB.(TIAN.)H YC1 Industry Peers by Asset Resilience Ratio
Compare ASYMCHEM LAB.(TIAN.)H YC1's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Hugel Inc
KQ:145020 |
Biotechnology | 29.57% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Theravance Biopharma Inc
F:0TB |
Biotechnology | 37.29% |
|
Wecome Pharmaceutical Co Ltd
SHE:300878 |
Biotechnology | 0.67% |
|
Beijing Scitop Bio Tech Co Ltd
SHE:300858 |
Biotechnology | 25.93% |
Annual Asset Resilience Ratio for ASYMCHEM LAB.(TIAN.)H YC1 (2021–2025)
The table below shows the annual Asset Resilience Ratio data for ASYMCHEM LAB.(TIAN.)H YC1.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 5.51% | €1.12 Billion ≈ $1.31 Billion |
€20.28 Billion ≈ $23.71 Billion |
-2.48pp |
| 2024-12-31 | 7.98% | €1.54 Billion ≈ $1.80 Billion |
€19.29 Billion ≈ $22.55 Billion |
-1.66pp |
| 2023-12-31 | 9.64% | €1.91 Billion ≈ $2.23 Billion |
€19.77 Billion ≈ $23.11 Billion |
-2.15pp |
| 2022-12-31 | 11.79% | €2.15 Billion ≈ $2.51 Billion |
€18.24 Billion ≈ $21.32 Billion |
+9.15pp |
| 2021-12-31 | 2.65% | €401.20 Million ≈ $469.04 Million |
€15.16 Billion ≈ $17.72 Billion |
-- |
About ASYMCHEM LAB.(TIAN.)H YC1
Asymchem Laboratories (Tianjin) Co., Ltd. provides contract development and manufacturing organization (CDMO) solutions in Mainland China and internationally. It is involved in small molecule CDMO services for projects covering multiple major disease treatment areas, such as oncology, antiviral, anti-infective, cardiovascular, and diabetes; chemical macromolecule CDMO; biomacromolecule CDMO, incl… Read more